T1	Claim 1 163	Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
T2	Premise 917 958	Ibandronate was generally well tolerated.
T3	Premise 959 1101	Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,
T4	Premise 1102 1201	but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).
T5	Premise 1202 1342	A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
T6	Premise 1343 1616	Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).
T7	Premise 1617 1727	Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
T8	Claim 1728 1923	I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.
R1	Support Arg1:T7 Arg2:T8	
R2	Support Arg1:T2 Arg2:T8	
R3	Partial-Attack Arg1:T4 Arg2:T3	
R4	Support Arg1:T3 Arg2:T8	
R5	Support Arg1:T5 Arg2:T8	
R6	Support Arg1:T6 Arg2:T8	
